Published in Hospital Law Weekly, May 1st, 2008
The trial is a placebo-controlled, randomized, double-blind, single center study involving 40 healthy, 18-40 year old, CMV-negative volunteers. The trial is being conducted by David I. Bernstein, M.D., Director of Infectious Diseases at the Cincinnati Children's Hospital Medical Center in Ohio. AlphaVax's CMV vaccine was administered three times over six months at one of two dosage levels, and safety and immunogenicity data were obtained from all volunteers following each dose of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly